Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597086 | 0.91 | SCN9A (1.00) | SCN9A | |
| SCHEMBL281707 | 0.85 | SCN9A (1.00) | SCN9A | |
| SCHEMBL4597622 | 0.84 | SCN9A (1.00) | SCN9A | |
| SCHEMBL4595875 | 0.83 | SCN9A (1.00) | SCN9A | |
| SCHEMBL4597092 | 0.82 | SCN9A (0.81) | SCN9A | |
| SCHEMBL4731135 | 0.81 | SCN9A (1.00) | SCN9A | |
| SCHEMBL4728008 | 0.81 | SCN9A (1.00) | SCN9A | |
| SCHEMBL4597679 | 0.81 | SCN9A (1.00) | SCN9A | |
| SCHEMBL4729548 | 0.81 | SCN9A (1.00) | SCN9A | |
| SCHEMBL5431061 | 0.80 | SCN9A (1.00) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101213174-A | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-07-02 | — | — | CN | claimed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | claimed |
| CN-101213174-A | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-07-02 | — | — | CN | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | SCN9A 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.